文献速递胸部PET

变异系数是一种简便易得的代谢异质性定量指标,可用于预测表现为中央型肺癌的早期及局部晚期非小细胞肺癌患者生存

COV is a readily available quantitative indicator of metabolic heterogeneity for predicting survival of patients with early and locally advanced NSCLC manifesting as central lung cancer.
PubMed 文献 · Eur J Radiol · 2020-10-08

回顾性纳入73例表现为中央型肺癌的非小细胞肺癌患者,用18F-FDG PET的变异系数(COV)评估代谢异质性。COV是总生存期的独立危险因素(HR 3.162,P=0.0002),最佳截断值23.1366对应敏感度0.737、特异度0.771;肺不张也是总生存期的独立危险因素(HR 2.047,P=0.041)。COV还是无进展生存期的显著预测因子(HR 2.636,P=0.001)。

要点

  • 治疗前18F-FDG PET的COV是中央型NSCLC总生存期和无进展生存期的独立预测因子。
  • COV最佳截断值23.1366,预测总生存的敏感度0.737、特异度0.771。
  • 肺不张的存在也是总生存期的不良预后危险因素(HR 2.047,P=0.041)。

核心结论

  • 治疗前代谢异质性参数COV可简便地预测表现为中央型肺癌的NSCLC患者的总生存期和无进展生存期,在预后风险分层中起重要作用;肺不张也可能是总生存期不良预后的危险因素。

研究设计与样本

  • 回顾性纳入73例病理确诊、表现为中央型肺癌的NSCLC患者,采用18F-FDG PET的COV评估代谢异质性,用单因素和多因素分析评价其对总生存期和无进展生存期的预测价值。

诊断标准与关键数值

  • COV预测总生存率的最佳截断值为23.1366,敏感度0.737、特异度0.771;以该值将COV二分类后与肺不张一起纳入Cox多因素分析,COV(HR 3.162,P=0.0002)和肺不张(HR 2.047,P=0.041)均为总生存期的独立危险因素;无进展生存期仅COV为显著预测因子(HR 2.636,P=0.001)。

临床应用与阅片要点

  • 对表现为中央型肺癌的早期及局部晚期NSCLC患者,治疗前18F-FDG PET测得的COV可用于预后风险分层;阅片时同时关注是否合并肺不张,因其与总生存期不良预后相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of our study was to investigate the value of a simple metabolic heterogeneity parameter, COV (coefficient of variation), by 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the prognosis prediction of central lung cancer in early and locally advanced non-small-cell lung cancer (NSCLC).

METHODS: Seventy-three patients with NSCLC manifesting as central lung cancer were included retrospectively, and we used the COV to evaluate metabolic heterogeneity. Univariate and multivariate analyses were used to evaluate the predictive value in terms of overall survival (OS) and progression-free survival (PFS).

RESULT: For all 73 patients with pathologically confirmed NSCLC, 69.9 % had SCC, and 30.1 % had ADC or other types of NSCLC. The COV was a statistically significant factor in the univariate analysis for the OS rate. The optimal cut-off value was 23.1366, with sensitivity = 0.737 and specificity = 0.771. The COV values were dichotomized by this value and included with atelectasis in the Cox multivariate analysis. Both COV and atelectasis were independent risk factors for OS as follows: for COV (HR, 3.162, P = 0.0002), the 2-year OS rate was 62.5 % and 26.9 % in the low and high COV groups, respectively. For atelectasis (HR 2.047, P = 0.041), the 2-year OS rate was 30.6 % and 65.2 % in the groups with and without atelectasis, respectively (P = 0.017). For PFS, only COV (HR, 2.636, P = 0.001) was a significant predictor. The 2-year PFS rate was 29.7 % in the low COV group and 8% in the high COV group.

CONCLUSION: The pre-treatment metabolic heterogeneity parameter COV is a simple and easy way to predict the OS and PFS of patients with NSCLC manifesting as central lung cancer. Therefore, COV plays an important role in prognostic risk classification in NSCLC. The presence of atelectasis could also be a risk factor for poor prognosis of OS.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Yu T. COV is a readily available quantitative indicator of metabolic heterogeneity for predicting survival of patients with early and locally advanced NSCLC manifesting as central lung cancer. Eur J Radiol. 2020. PMID: 33068840. doi:10.1016/j.ejrad.2020.109338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。